Healthcare
Exelixis, Inc.
EXEL$56.89+4.12%
Price is delayed.
Add to Watchlist
About Exelixis, Inc.
Exelixis is a biotechnology company that develops and sells cancer medicines. It markets two drugs derived from cabozantinib: Cabometyx, used to treat advanced kidney cancer, and Cometriq, used to treat a type of thyroid cancer. The company also sells Cotellic for certain melanomas and Minnebro for high blood pressure in Japan. Exelixis has a pipeline of experimental drugs in development aimed at various cancers.
Loading chart...
Members only
Full research is for ConvictionStocks members
Members read the rest of this page. Where we have it for this company, that is:
- What each number means, in plain English, with the Wall Street name where the two differ.
- A plain-English summary of the company.
- How many analysts cover it, and the count behind each rating.
- Recent news, dated.
Get the free weekly market digest
The week's biggest movers, every Sunday. No spam.
Look up another company
Related Research
More Healthcare stocks to explore